|
|
|
|
Earnings Preview: Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)
Teva Pharmaceutical Industries (TEVA), the world's leading generic pharmaceuticals company, is scheduled to report Q4 FY2009 results on Tuesday, February 16, 2010.In the last four quarters ending September 2009, the company's earnings bettered the analysts'...
|
|
|
Study to look at earlier use of MS drug Tysabri
As regulators once again updated the label on Tysabri over the risk of a rare and potentially fatal brain disease, Biogen Idec and Elan Corp are planning a long-term trial that could lead to use of the multiple sclerosis blockbuster at the early stages of the...
|
|
|
Biogen Plans First Study For Earlier Use Of MS Drug Tysabri
NEW YORK -(Dow Jones)- Biogen Idec Inc.(BIIB) is planning the first clinical trial that could lead to use of controversial multiple sclerosis treatment Tysabri, sold with Elan Corp. (ELN), at earlier stages of the disease. The long-term trial, dubbed...
|
|
|
Biogen Plans First Study For Earlier Use Of MS Drug Tysabri
NEW YORK -(Dow Jones)- Biogen Idec Inc.(BIIB) is planning the first clinical trial that could lead to use of controversial multiple sclerosis treatment Tysabri, sold with Elan Corp. (ELN), at earlier stages of the disease. The long-term trial, dubbed...
|
|
|
Biogen Plans First Study For Earlier Use Of MS Drug Tysabri
NEW YORK -(Dow Jones)- Biogen Idec Inc.(BIIB) is planning the first clinical trial that could lead to use of controversial multiple sclerosis treatment Tysabri, sold with Elan Corp. (ELN), at earlier stages of the disease. The long-term trial, dubbed...
|
|
|
Biogen Plans First Study For Earlier Use Of MS Drug Tysabri
NEW YORK -(Dow Jones)- Biogen Idec Inc.(BIIB) is planning the first clinical trial that could lead to use of controversial multiple sclerosis treatment Tysabri, sold with Elan Corp. (ELN), at earlier stages of the disease. The long-term trial, dubbed...
|
|
|
Biogen Plans First Study For Earlier Use Of MS Drug Tysabri
NEW YORK -(Dow Jones)- Biogen Idec Inc.(BIIB) is planning the first clinical trial that could lead to use of controversial multiple sclerosis treatment Tysabri, sold with Elan Corp. (ELN), at earlier stages of the disease. The long-term trial, dubbed...
|
|
|
Lawsuit against TEVA's COPAXONE for a ALS clinical trial/misethical issues
the following news article was published in the Israeli daily journal 'yedioth aharonot' Three Israeli ALS patients (ALS- amyotrophic lateral sclerosis), are seeking millions from an Israeli pharmaceutical company 'TEVA'.'We were the guinea pigs of 'TEVA' '....
|
|
|
Todays Zacks Rank Growth and Income Buy: Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd.(TEVA - Analyst Report) recently presented an updated its strategy for growth. The company plans to achieve revenues of $31 billion and non-GAAP net income of $6.8 billion by 2015. Management said its core business,...
|
|
|
No Way to Hide This Drug Approval
Friday evening is usually a good time for companies to bury bad news, but that wasn't the case for Acorda Therapeutics (Nasdaq: ACOR).The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk...
|
|
|
Tysabri Updates: All You Have to Do Is Ask
Recs 0 //Create your sharelet with desired properties and set button element to false object //Tie customized button to This button functionality.element Disney Buys Marvel! David Gardner called it! Hes up 1,334%! See what Davids recommending that you...
|
|
|
No Way to Hide This Drug Approval
Friday evening is usually a good time for companies to bury bad news, but that wasn't the case for Acorda Therapeutics (Nasdaq: ACOR).The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk...
|
|
|
Tysabri Updates: All You Have to Do Is Ask
Recs 0 //Create your sharelet with desired properties and set button element to false object //Tie customized button to This button functionality.element Disney Buys Marvel! David Gardner called it! Hes up 1,334%! See what Davids recommending that you...
|
|
|
Oral MS Drugs Effective in Phase III Trials
Two oral drugs under investigation for multiple sclerosis reduced relapse rates and delayed onset of disability in separate trials reported online this week in the New England Journal of Medicine.Fingolimod, a novel agent also known as FTY-720, was more...
|
|
|
Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrend
EXTON, Pa., Jan.11 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends: EXTAVIA report. The survey was completed by U.S. Neurologists (n=76) in November and December 2009, approximately one month following...
|
|
|
Biomedix Incubator invests in new ventures with Roche: The incubator company also merged an additional start-u
Biomedix Incubator Ltd.(TASE:BMDX) today announced joint investments with Roche AG (SWX: RO) in four new ventures and the merger of a start-up into portfolio company Elutex Ltd. (TASE:ELTX). The investments are the first actions under the strategic...
|
|
|
A generic-giant juggernaut called Teva Pharma
Before Israel Makov stepped down as chief executive officer of Teva Pharmaceutical in 2007, he had told investment analysts that Tevas future pipeline of innovative products will be envied by the multinationals.Today Teva has a market capitalisation of $54...
|
|
|
$15 bln of acquisitions to power Teva growth
By Tova Cohen TEL AVIV, Jan 13 (Reuters) - The plan by Teva Pharmaceutical Industries to more than double revenue by 2015 will be backed by $15 billion of acquisitions of niche products and in regions where its presence is weak.With $150 billion worth of...
|
|
|
Biogen: 28 Cases Of Brain Infection In Tysabri As Of Mid-Dec
Tysabri treatment, which it sells with (ELN).Mullen provided the update at JPMorgan's health-care conference in San Francisco on Tuesday. The rate of the infection, progressive multifocal leukoencephalopathy, or PML, continues to be about 1 in 1,000...
|
|
|
BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report
BioTrends Research Group, Inc.announces the release of the Wave One LaunchTrends(): EXTAVIA report. The survey was completed by U.S. Neurologists Extavia (Interferon beta 1b). Awareness of Extavia is relatively high but familiarity is more moderate.
|
|
|
Tysabri: It's a Blockbuster! Yawn. So What?
Recs 3 //Create your sharelet with desired properties and set button element to false object //Tie customized button to This button functionality.element Disney Buys Marvel! David Gardner called it! Hes up 1,334%! See what Davids recommending that you...
|
|
|
Tysabri: It's a Blockbuster! Yawn. So What?
David Gardner called it.Hes up 1,334%! See what Davids recommending that you buy NEXT! The financial press can finally drop the 'potential' in front of blockbuster when describing Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) multiple sclerosis drug,...
|
|
|
Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA
EXTON, Pa., Jan.11 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends: EXTAVIA report. The survey was completed by U.S. Neurologists (n=76) in November and December 2009, approximately one month following...
|
|
|
Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA
EXTON, Pa., Jan.11 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends: EXTAVIA report. The survey was completed by U.S. Neurologists (n=76) in November and December 2009, approximately one month following...
|
|
|
Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA
EXTON, Pa., Jan.11 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends: EXTAVIA report. The survey was completed by U.S. Neurologists (n=76) in November and December 2009, approximately one month following...
|
